At the right time: Moving precision therapy to newly diagnosed cancer

Adam Wahida; Ben George; Razelle Kurzrock

doi:10.1016/j.medj.2024.10.017

At the right time: Moving precision therapy to newly diagnosed cancer

Med. 2024 Dec 13;5(12):1463-1465. doi: 10.1016/j.medj.2024.10.017.

Authors

Adam Wahida¹, Ben George², Razelle Kurzrock³

Affiliations

¹ Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany. Electronic address: [email protected].
² MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
³ MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA; WIN Consortium, Paris, France. Electronic address: [email protected].

PMID: 39674173
DOI: 10.1016/j.medj.2024.10.017

Abstract

Precision oncology aims to match the right drug(s) to the right patient. Equally important is ensuring that precision therapies are offered at the right time. Transformative, rather than incremental, outcome improvement may require treatment at diagnosis rather than in the advanced/metastatic setting after genomic evolution.

MeSH terms

Antineoplastic Agents / therapeutic use
Humans
Neoplasms* / diagnosis
Neoplasms* / drug therapy
Neoplasms* / genetics
Neoplasms* / therapy
Precision Medicine* / methods

Substances

Antineoplastic Agents